BCDA BioCardia Inc

Price (delayed)

$1.05

Market cap

$15.9M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.64

Enterprise value

$12.07M

?
Relative Growth: Rel. Growth: 20
Relative Strength: Rel. Strength: 33
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 5

BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s ...

Highlights
The EPS has soared by 65% YoY and by 30% from the previous quarter
The debt has dropped by 61% year-on-year and by 29% since the previous quarter

Key stats

What are the main financial stats of BCDA

BCDA stock price

How has the BioCardia stock price performed over time
Intraday
0%
1 week
-16%
1 month
3.96%
1 year
-25.53%
YTD
-16%
QTD
-15.32%

Financial performance

How have BioCardia's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$7.39M
Net income
-$7.34M
Gross margin
N/A
Net margin
N/A
BioCardia's operating income has increased by 17% YoY and by 5% from the previous quarter
BioCardia's net income has increased by 17% YoY and by 6% from the previous quarter

Price vs fundamentals

How does BCDA's price correlate with its fundamentals

Growth

What is BioCardia's growth rate over time

Valuation

What is BioCardia stock price valuation
P/E
N/A
P/B
4.42
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 65% YoY and by 30% from the previous quarter

Efficiency

How efficient is BioCardia business performance
The company's return on equity has surged by 97% YoY and by 90% QoQ
The ROA has grown by 26% YoY and by 21% from the previous quarter

Dividends

What is BCDA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BCDA.

Financial health

How did BioCardia financials performed over time
BCDA's total assets is 131% higher than its total liabilities
BCDA's total assets has soared by 178% QoQ and by 128% YoY
BioCardia's total liabilities has decreased by 48% YoY and by 26% QoQ
The debt is 89% smaller than the equity
BioCardia's debt to equity has soared by 128% from the previous quarter and by 128% YoY
The debt has dropped by 61% year-on-year and by 29% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.